(NASDAQ: PACB) Pacific Biosciences Of California's forecast annual revenue growth rate of 12.54% is forecast to beat the US Medical Devices industry's average forecast revenue growth rate of 9%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 13.46%.
Pacific Biosciences Of California's revenue in 2026 is $160,005,000.On average, 11 Wall Street analysts forecast PACB's revenue for 2026 to be $53,743,616,044, with the lowest PACB revenue forecast at $51,043,751,314, and the highest PACB revenue forecast at $56,443,480,775. On average, 11 Wall Street analysts forecast PACB's revenue for 2027 to be $60,414,758,315, with the lowest PACB revenue forecast at $56,232,081,970, and the highest PACB revenue forecast at $63,419,641,320.
In 2028, PACB is forecast to generate $69,236,128,424 in revenue, with the lowest revenue forecast at $61,233,173,686 and the highest revenue forecast at $77,317,602,718.